December 28, 2011 STRAKAN INTERNATIONAL S.À R.L. PROSTRAKAN INC. (For the Purposes of Sections 5.1 and 11.1.2) – and – APTALIS PHARMA US, INC. Commercialization and License AgreementCommercialization and License Agreement • December 17th, 2013 • Aptalis Holdings Inc. • Pharmaceutical preparations • New York
This COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is dated as of December 28, 2011 (the “Signing Date”), but shall not be effective until the Effective Date, by and among STRAKAN INTERNATIONAL S.À R.L., a company incorporated under the Laws of Luxembourg having a principal place of business at Galabank Business Park, Galashiels, Scottish Borders, TD1 1QH UK (“Strakan”), and PROSTRAKAN INC., for the purposes of Sections 5.1 and 11.1.2, a company incorporated under the Laws of Delaware having a principal place of business at 1430 State Highway 206, Suite 101, Bedminster, NJ 07921, US (“ProStrakan”), on the one hand, and APTALIS PHARMA US, INC. a company incorporated under the Laws of the State of Delaware and having a principal place of business at 22 Inverness Center Parkway, Birmingham, Alabama 35242, United States (“Aptalis”) on the other hand. Strakan and Aptalis are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTCommercialization and License Agreement • February 23rd, 2007 • Senomyx Inc • Services-commercial physical & biological research • California
This First Amendment is entered into as of October 6, 2006, by and between Senomyx, Inc. (“Senomyx”) and Ajinomoto Co., Inc. (“Ajinomoto”). Capitalized terms used herein without definition shall have the meaning provided therefor in the First Collaboration Agreement (as defined below).
COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN EVELO BIOSCIENCES, INC. AND MEDDIST COMPANY LIMITED Dated 17 March 2021Commercialization and License Agreement • March 23rd, 2021 • Evelo Biosciences, Inc. • Pharmaceutical preparations • New York
THIS COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of 17 March 2021 (the “Effective Date”) by and between EVELO BIOSCIENCES, INC., a corporation organized and existing under the laws of Delaware (“Evelo”), and MEDDIST COMPANY LIMITED, a company organized and existing under the laws of Jersey (“ALJ”). Evelo and ALJ are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
TERMINATION OF COLLABORATIVE COMMERCIALIZATION AND LICENSE AGREEMENTCommercialization and License Agreement • March 15th, 2006 • Catalytica Energy Systems Inc • Engines & turbines
This Termination of Collaborative Commercialization and License Agreement (this “Termination Agreement”) is entered into effective as of the last date set forth in the signatures below (the “Effective Date”) by and between General Electric Company, new York corporation (“hereinafter GE”) and Catalytica Energy Systems, Inc., a Delaware corporation (“hereinafter CESI”), hereinafter referred to as Party or parties, respectively.
Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K. COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN UNIQURE BIOPHARMA BV AND CSL BEHRING LLC Dated June 24, 2020Commercialization and License Agreement • July 30th, 2020 • uniQure N.V. • Pharmaceutical preparations • New York
This COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is made as of June 24, 2020 (the “Execution Date”) by and between uniQure biopharma BV, a corporation organized under the laws of the Netherlands, having its principal place of business at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure”), and CSL Behring LLC, a limited liability company organized and existing under the laws of Delaware, having a registered office located at 1020 First Avenue, King of Prussia, PA 19406, United States (“Partner”). uniQure and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.Commercialization and License Agreement • March 13th, 2020 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Commercialization and License Agreement (this “Agreement”) is made as of November 5, 2019 (the “Effective Date”) by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), having a place of business at 4505 Emperor Boulevard, Suite 200, Durham, NC 27703, USA, and Torii Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan (“Torii”), having a place of business at 4-1 Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo, Japan. BioCryst and Torii are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. COMMERCIALIZATION AND LICENSE AGREEMENTCommercialization and License Agreement • January 9th, 2020 • CytoDyn Inc. • Pharmaceutical preparations • New York
This Commercialization and License Agreement (this “Agreement”) is made effective as of December 17, 2019 (the “Effective Date”) by and between Vyera Pharmaceuticals, LLC, a Delaware limited liability company (“Vyera”), and CytoDyn Inc., a Delaware corporation (“CytoDyn”). CytoDyn and Vyera are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
